Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Parallel-group, Randomized, Prospective, Interventional, Double-blind, Multicenter Global Phase 3 Study to Investigate the Efficacy and Safety of Finerenone Versus Placebo, in Addition to Standard of Care, in Participants With Chronic Kidney Disease and Type 1 Diabetes

NCT05901831 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT05901831
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05901831 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Parallel-group, Randomized, Prospective, Interventional, Double-blind, Multicenter Global Phase 3 Study to Investigate the Efficacy and Safety of Finerenone Versus Placebo, in Addition to Standard of Care, in Participants With Chronic Kidney Disease and Type 1 Diabetes
Lead sponsor
Bayer
Phase
Phase 3
Overall status
Completed
Start date
February 26, 2024
Completion date
September 15, 2025
Enrollment
241 (actual)
Sites
80

Conditions

As the registry lists them; a condition with its own page is linked.

chronic kidney disease, type 1 diabetes mellitus